ABBVAbbVie

Health care · Pharmaceuticals · NYSE

AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. 10-K, Item 1

ABBV quote by TradingView

Employees: 57,000
Headquarters: North Chicago, IL
Next results: around Jan 6, 2027

Compare with peers →

X LinkedIn Reddit WhatsApp Telegram Image

Embed

What changed 8new risk paragraphs 1accounting checks to look at 0insider buys, 90 days 4filings in 30 days

Overview Numbers What changed Owners and insiders Filings Your tools

New risk factors8 10-K change Accounting checks1 Said vs did Why it changed Related parties SEC letters

Deals between ABBV and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement. Below: what the proxy filed 2026-03-23 reports that the one filed 2025-03-24 did not, quoted as filed.

New this year

Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed 2025-03-24.

Nothing new: every deal in this year's section was reported last year too.

The whole section 11 paragraphs, proxy filed 2026-03-23

Procedures for Approval of Related Person Transactions

“It is AbbVie’s policy that the nominations and governance committee conduct a reasonable prior review and approve or disapprove of all transactions in which AbbVie participates and in which any related person has a direct or indirect material interest if such transaction involves or is expected to involve payments of $120,000 or more in the aggregate per fiscal year. Related person transactions requiring review by the nominations and governance committee pursuant to this policy are identified in:”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“questionnaires annually distributed to AbbVie’s directors and executive officers;”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“certifications submitted annually by AbbVie executive officers related to their compliance with AbbVie’s Code of Business Conduct; or communications made directly by the related person to the chief financial officer or general counsel.”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“In determining whether to approve or disapprove a related person transaction, the nominations and governance committee will consider the following items, among others:”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“the material facts of the transaction, including the aggregate value of such transaction or, in the case of indebtedness, the amount of principal involved;”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“if applicable, the availability of other sources of comparable products or services;”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“an assessment of whether the transaction is on terms that are comparable to the terms available to an unrelated third party or to employees generally;”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“whether a transaction has the potential to impair director independence; and whether the transaction constitutes a conflict of interest.”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“This process is included in the nominations and governance committee’s written charter, which is available on the governance section of AbbVie’s investor relations website at www.abbvieinvestor.com.”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“Nicholas Donoghoe, M.D., Executive Vice President, Chief Business and Strategy Officer, was appointed as an executive officer of AbbVie during 2023. Dr. Donoghoe’s wife, Jessica Heckmann Donoghoe, is a minority equity owner in LaserAway, a chain of aesthetics clinics. Dr. Donoghoe’s brothers-in-law Brock Heckmann, Scott Heckmann, and Todd Heckmann are also equity owners, as well as executives, at LaserAway. LaserAway purchased $17.7 million worth of AbbVie products during 2025, including Botox Cosmetic, Juvederm, and Coolsculpting. LaserAway also receives product samples for educational and other training purposes. Dr. Donoghoe does not have any visibility to or control or influence over the terms of the LaserAway transactions. LaserAway first became a customer of the Allergan group of companies before AbbVie acquired Allergan in 2020. Our nominations and governance committee, pursuant to its committee charter, has reviewed and approved the foregoing arrangement with LaserAway.”
Read it in the proxy ↗

Procedures for Approval of Related Person Transactions

“Alexander Freyman, who is the son of Thomas Freyman, a director of the company, is an employee at AbbVie. Alexander earned $145,293.47 in total compensation in 2025. Thomas Freyman has no role in setting Alexander’s compensation, performance evaluations, or any other aspects of his employment. Alexander’s compensation is on terms that are comparable to the terms available to similarly situated employees. Our nominations and governance committee, pursuant to its committee charter, has reviewed and approved Alexander’s compensation. Thomas Freyman recused himself from this review and approval.”
Read it in the proxy ↗

Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗

Work on ABBV in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/ABBV/export.csv") into a cell.